| scholarly article | Q13442814 |
| P50 | author | Gabriele S. Leverich | Q111732463 |
| Robert M. Post | Q87613308 | ||
| P2093 | author name string | Brandt D | |
| Nolen W | |||
| Spearing MK | |||
| P2860 | cites work | Intraclass correlations: uses in assessing rater reliability | Q28296226 |
| Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation | Q34727859 | ||
| Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. | Q34744028 | ||
| "Clinical Global Impressions" (ECDEU): some critical comments | Q38472817 | ||
| Refractory depression: the addition of lithium to fluoxetine or desipramine. | Q41162871 | ||
| The place of anticonvulsant therapy in bipolar illness | Q41257728 | ||
| Practicable and valid approach to evaluate the efficacy of nootropic drugs by means of rating scales | Q48678058 | ||
| Testosterone replacement therapy in HIV illness. | Q51128527 | ||
| Efficacy of xantinolnicotinate in patients with dementia. | Q53033917 | ||
| Identification of true drug response to antidepressants. Use of pattern analysis | Q70366893 | ||
| A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients | Q70595011 | ||
| A clinical study of clozapine treatment and predictors of response in a Canadian sample | Q71916632 | ||
| Effects of carbamazepine and lithium on affective disorders | Q72586329 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 159-171 | |
| P577 | publication date | 1997-12-01 | |
| P1433 | published in | Psychiatry Research | Q15750888 |
| P1476 | title | Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. | |
| P478 | volume | 73 |
| Q28730355 | A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state |
| Q91760395 | A 6-Month, Prospective, Randomized Controlled Trial of Customized Adherence Enhancement Versus Bipolar-Specific Educational Control in Poorly Adherent Individuals With Bipolar Disorder |
| Q34315306 | A Pharmacological Functional Magnetic Resonance Imaging Study Probing the Interface of Cognitive and Emotional Brain Systems in Pediatric Bipolar Disorder |
| Q48481210 | A brief cognitive-behavioral intervention for treating depression and panic disorder in patients with noncardiac chest pain: a 24-week randomized controlled trial |
| Q38952459 | A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). |
| Q51951720 | A clinical monitoring form for mood disorders. |
| Q38467316 | A global measure to assess switching antipsychotic medications in the treatment of schizophrenia |
| Q30827408 | A novel application of the Intent to Attend assessment to reduce bias due to missing data in a randomized controlled clinical trial |
| Q47878230 | A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use. |
| Q34649372 | A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania |
| Q47219944 | A prospective observational study of problematic oral cannabinoid use. |
| Q36635790 | A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents |
| Q35838572 | A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression |
| Q47696307 | A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. |
| Q51909168 | A relative resistance of T cells to dexamethasone in bipolar disorder. |
| Q37107425 | A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression |
| Q36588803 | A structured interview guide for global impressions: increasing reliability and scoring accuracy for CNS trials |
| Q47731766 | Abnormal sleep duration associated with hastened depressive recurrence in bipolar disorder. |
| Q48602776 | Achieving and sustaining remission in bipolar I disorder with ziprasidone : a post hoc analysis of a 24-week, double-blind, placebo-controlled study |
| Q53905612 | Acute and continuation pharmacological treatment of children and adolescents with bipolar disorders; a summary of two previous studies. |
| Q44272770 | Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design |
| Q37059108 | Adaptive Interventions in Child and Adolescent Mental Health |
| Q24619584 | Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study |
| Q96769981 | Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials |
| Q53900501 | Adjunctive gabapentin treatment of bipolar disorder. |
| Q34060640 | Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms |
| Q34223084 | Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. |
| Q44452755 | Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation |
| Q44649446 | Adjunctive topiramate in bipolar II disorder |
| Q50203222 | Adolescent and Family-focused Cognitive-behavioural Therapy for Paediatric Bipolar Disorders: A Case Series. |
| Q37309682 | Advanced Circadian Phase in Mania and Delayed Circadian Phase in Mixed Mania and Depression Returned to Normal after Treatment of Bipolar Disorder. |
| Q47661531 | Aggressiveness in depression: a neglected symptom possibly associated with bipolarity and mixed features |
| Q37608023 | American tertiary clinic-referred bipolar II disorder versus bipolar I disorder associated with hastened depressive recurrence |
| Q24656287 | Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial |
| Q49962753 | An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS). |
| Q35690464 | An Integrated Risk Reduction Intervention can reduce body mass index in individuals being treated for bipolar I disorder: results from a randomized trial |
| Q92283975 | An adjunctive human-animal interaction intervention for veterans with PTSD: study protocol for a randomized controlled trial |
| Q35428586 | An exploratory study of responses to low-dose lithium in African Americans and Hispanics. |
| Q51897566 | An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. |
| Q42682051 | An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients |
| Q35017346 | An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients |
| Q80289133 | An open-label study of quetiapine in anorexia nervosa |
| Q37798477 | An overview of mood disorders in the DSM-5. |
| Q30482552 | An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). |
| Q45181461 | Anxiety as a marker of severity in acute mania |
| Q45912821 | Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials. |
| Q34926160 | Are clinicians' assessments of improvements in children's functioning "global"? |
| Q43145175 | Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study |
| Q46886132 | Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study |
| Q89052840 | Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study |
| Q48793990 | Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial |
| Q47783378 | Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review |
| Q47796261 | Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control |
| Q90667277 | Asenapine in the Treatment of Bipolar Depression |
| Q36794665 | Asenapine in the treatment of older adults with bipolar disorder |
| Q47876421 | Assessing bipolar disorder in the older adult: the GERI-BD toolbox |
| Q47325373 | Assessing the affective load in the narratives of women suffering from fibromyalgia: the clinicians' appraisal |
| Q44393866 | Assessment of treatment response in mania: commentary and new findings |
| Q47651644 | Associations of Comorbid Anxiety With Medication Adherence and Psychiatric Symptomatology in a Population of Nonadherent Bipolar Disorder Subjects |
| Q58605290 | B-positive: a randomized controlled trial of a multicomponent positive psychology intervention for euthymic patients with bipolar disorder - study protocol and intervention development |
| Q48348725 | Bilateral subthalamic nucleus stimulation for generalized dystonia after bilateral pallidotomy |
| Q38097548 | Bipolar depression in children and adolescents |
| Q33435703 | Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting |
| Q36488057 | Brain-derived neurotrophic factor val66met genotype and early life stress effects upon bipolar course |
| Q42631319 | Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18-month pilot study |
| Q50456665 | Cannabis and bipolar disorder: does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? |
| Q36257188 | Carbamazepine extended-release capsules: a new treatment option for bipolar I disorder |
| Q49611619 | Cardiovascular risk and bipolar disorder: factors associated with a positive coronary calcium score in patients with bipolar disorder type 1. |
| Q47701755 | Changes in energy and motor activity: core symptoms of bipolar mania and depression? |
| Q47745367 | Changes in white matter microstructure predict lithium response in adolescents with bipolar disorder. |
| Q36759143 | Characteristics associated with inpatient versus outpatient status in older adults with bipolar disorder. |
| Q34139293 | Child Mania Rating Scale-Parent Version: a valid measure of symptom change due to pharmacotherapy |
| Q30370127 | Child- and family-focused cognitive-behavioral therapy for pediatric bipolar disorder: a randomized clinical trial |
| Q43900135 | Chronic mania revisited: factors associated with treatment non-response during prospective follow-up of a large European cohort (EMBLEM). |
| Q42179329 | Chronic mania: an underrecognized clinical entity |
| Q90366882 | Clinical applications of transcranial magnetic stimulation in bipolar disorder |
| Q34925861 | Clinical management and burden of bipolar disorder: a multinational longitudinal study (WAVE-bd study) |
| Q43618621 | Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). |
| Q40661158 | Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders |
| Q34332307 | Clinical significance of treatment effects with aripiprazole versus placebo in a study of manic or mixed episodes associated with pediatric bipolar I disorder |
| Q47656515 | Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder |
| Q52021795 | Clinician ratings vs. global ratings of symptom severity: a comparison of symptom measures in the bipolar disorder module, phase II, Texas Medication Algorithm Project. |
| Q60047653 | Cognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS): Rationale, Design, and Characteristics |
| Q47563476 | Cognitive functioning following stabilisation from first episode mania |
| Q24814468 | Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder |
| Q34833550 | Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study |
| Q38707913 | Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder |
| Q39136651 | Comparison of two anticonvulsants in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder |
| Q34575982 | Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD |
| Q39178954 | Continuous circular cycling as a predictor of treatment response in bipolar disorders: a comprehensive review of the current literature |
| Q37332724 | Correlates of current suicide risk among Thai patients with bipolar I disorder: findings from the Thai Bipolar Disorder Registry. |
| Q39890955 | Correlation Between Insight Level and Suicidal Behavior/Ideation in Bipolar Depression. |
| Q92555890 | Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials |
| Q33414015 | Course and outcome after the first manic episode in patients with bipolar disorder: prospective 12-month data from the Systematic Treatment Optimization Program For Early Mania project |
| Q37139273 | Current irritability associated with hastened depressive recurrence and delayed depressive recovery in bipolar disorder |
| Q38297855 | Current landscape, unmet needs, and future directions for treatment of bipolar depression |
| Q33920910 | Current nosology of treatment resistant depression: a controversy resistant to revision |
| Q30996987 | Data quality indicators for daily life chart methodology: prospective self-ratings of bipolar disorder and alcohol use. |
| Q97592368 | Deconstructing major depressive episodes across unipolar and bipolar depression by severity and duration: a cross-diagnostic cluster analysis on a large, international, observational study |
| Q47573921 | Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression |
| Q44594822 | Description of study population and analysis of factors influencing adherence in the observational Italian study "Evaluation of Pharmacotherapy Adherence in Bipolar Disorder" (EPHAR). |
| Q48195966 | Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression |
| Q34163069 | Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale |
| Q45331015 | Development and validation of the Affective Self Rating Scale for manic, depressive, and mixed affective states |
| Q36860514 | Development of an integrated psychosocial treatment to address the medical burden associated with bipolar disorder |
| Q37567426 | Differential Anterior Cingulate Activity during Response Inhibition in Depressed Adolescents with Bipolar and Unipolar Major Depressive Disorder |
| Q52673200 | Differential effect of quetiapine and lithium on functional connectivity of the striatum in first episode mania. |
| Q48338339 | Differential patterns of neuropsychological performance in the euthymic and depressive phases of bipolar disorders |
| Q46494857 | Divalproex sodium for pediatric mixed mania: a 6-month prospective trial |
| Q34503303 | Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder? |
| Q34700817 | Does age at onset have clinical significance in older adults with bipolar disorder? |
| Q33820164 | Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention |
| Q33691400 | Does the number of previous mood episodes moderate the relationship between alcohol use, smoking and mood in bipolar outpatients? |
| Q34455825 | Double‐blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder |
| Q34217217 | ECNP Consensus Meeting March 2000 Nice: guidelines for investigating efficacy in bipolar disorder. European College of Neuropsychopharmacology |
| Q40169692 | Early detection and integrated care for adolescents and young adults with psychotic disorders: the ACCESS III study. |
| Q40585562 | Early detection and integrated care for adolescents and young adults with severe psychotic disorders: rationales and design of the Integrated Care in Early Psychosis Study (ACCESS III). |
| Q36143460 | Eating disorders and illness burden in patients with bipolar spectrum disorders |
| Q33961092 | Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial |
| Q48325863 | Effect of alcohol use on the course of bipolar disorder: one-year follow-up study using the daily prospective Life Chart method |
| Q42645625 | Effect of micronutrients on behavior and mood in adults With ADHD: evidence from an 8-week open label trial with natural extension |
| Q33553208 | Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico |
| Q42635317 | Effectiveness and weight effects of open-label lamotrigine with and without concomitant psychotropic medications in patients with bipolar I disorder. |
| Q37216281 | Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder |
| Q33712815 | Effectiveness of the Dader Method for pharmaceutical care in patients with bipolar I disorder: EMDADER-TAB: study protocol for a randomized controlled trial |
| Q44317309 | Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study |
| Q21260328 | Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials |
| Q57818062 | Effects of childhood trauma on adult moral decision-making: Clinical correlates and insights from bipolar disorder |
| Q44783760 | Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial |
| Q36083077 | Efficacy and Safety of Once- versus Twice-Daily Carbamazepine Extended-Release Capsules for the Treatment of Manic Symptoms in Patients with Bipolar I Disorder. |
| Q34063590 | Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial |
| Q37213281 | Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Chinese subpopulation analysis of a double-blind, randomized, placebo-controlled study |
| Q34722076 | Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study |
| Q48063091 | Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial |
| Q34034322 | Efficacy and tolerability of injectable sodium valproate in patients with mania |
| Q57476891 | Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial |
| Q48310435 | Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study |
| Q36618022 | Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study. |
| Q24234841 | Electroconvulsive therapy for depression |
| Q53962417 | Electroconvulsive therapy in treatment-resistant mania: case reports. |
| Q58117446 | Employment Service Provider Knowledge of Service User Assistance Needs |
| Q35992713 | Enhancing outcomes in patients with bipolar disorder: results from the Bipolar Disorder Center for Pennsylvanians Study |
| Q35586518 | Evaluating depressive symptoms in mania: a naturalistic study of patients with bipolar disorder |
| Q46901288 | Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study |
| Q46984808 | Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials |
| Q30843923 | Eye movement desensitization and reprocessing therapy versus supportive therapy in affective relapse prevention in bipolar patients with a history of trauma: study protocol for a randomized controlled trial |
| Q57612744 | Functional impairment in patients with mania: baseline results of the EMBLEM study |
| Q53895639 | Gabapentin in the acute treatment of refractory bipolar disorder. |
| Q42649543 | Gabapentin treatment of the non-refractory bipolar spectrum: an open case series |
| Q50557613 | Gender differences in outcomes of acute mania: a 12-month follow-up study. |
| Q45053879 | Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). |
| Q37213547 | General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. |
| Q47627637 | Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis. |
| Q34141209 | Group interpersonal and social rhythm therapy for bipolar depression |
| Q53835593 | Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. |
| Q38985017 | Identifying and describing patients' learning experiences towards self-management of bipolar disorders: a phenomenological study |
| Q38805394 | Impact of irritability: a 2-year observational study of outpatients with bipolar I or schizoaffective disorder |
| Q37284325 | Impaired fixation to eyes during facial emotion labelling in children with bipolar disorder or severe mood dysregulation |
| Q42782240 | Increasing the Sensitivity of Measures to Change |
| Q41569682 | Insight Across the Different Mood States of Bipolar Disorder. |
| Q40249319 | Insight in bipolar disorder: a comparison between mania, depression and euthymia using the Insight Scale for Affective Disorders |
| Q38640149 | Interactions Between Variation in Candidate Genes and Environmental Factors in the Etiology of Schizophrenia and Bipolar Disorder: a Systematic Review |
| Q48264004 | Is melatonin an adjunctive stabilizer? |
| Q37349962 | Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. |
| Q36233958 | Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study |
| Q36806521 | Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder |
| Q53930598 | Lamotrigine for the treatment of bipolar disorder: a clinical case series. |
| Q35925666 | Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study |
| Q41366608 | Lifetime eating disorder comorbidity associated with delayed depressive recovery in bipolar disorder |
| Q34474219 | Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study |
| Q53064542 | Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. |
| Q42640514 | Lithium treatment -- moderate dose use study (LiTMUS) for bipolar disorder: rationale and design |
| Q35568324 | Lithium treatment effects on Myo-inositol in adolescents with bipolar depression |
| Q46378835 | Long-chain omega-3 polyunsaturated fatty acids in the blood of children and adolescents with juvenile bipolar disorder. |
| Q37246368 | Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial |
| Q43608273 | Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series |
| Q93050367 | Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression |
| Q34340590 | Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. |
| Q48910862 | Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design |
| Q33885418 | Long-term response to mood stabilizer treatment and its clinical correlates in patients with bipolar disorders: a retrospective observational study |
| Q37675302 | Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment |
| Q37738207 | Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review |
| Q44290898 | Low CSF somatostatin associated with response to nimodipine in patents with affective illness |
| Q46498328 | Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. |
| Q38411188 | Lurasidone: a new treatment option for bipolar depression-a review |
| Q34379367 | Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial |
| Q45842412 | Mania in the Nordic countries: patients and treatment in the acute phase of the EMBLEM study |
| Q31043571 | Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. |
| Q41633664 | Mediators in the randomized trial of Child- and Family-Focused Cognitive-Behavioral Therapy for pediatric bipolar disorder |
| Q50627364 | Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). |
| Q39599238 | Medication Adherence Among Adolescents with Bipolar Disorder |
| Q37684910 | Medication adherence in a comparative effectiveness trial for bipolar disorder. |
| Q34052847 | Methodological issues in developing new acute treatments for patients with bipolar illness. |
| Q36979321 | Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the Lithium Treatment - Moderate dose Use Study (LiTMUS) for bipolar disorder |
| Q36687442 | Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate |
| Q34133042 | Mindfulness-based cognitive therapy versus psychoeducational intervention in bipolar outpatients with sub-threshold depressive symptoms: a randomized controlled trial |
| Q92260281 | Mindfulness-based social cognition training (SocialMIND) versus psychoeducational multicomponent intervention for people with a first episode of psychosis: a study protocol for a randomised controlled trial |
| Q46118665 | Misdiagnosis of bipolar disorder as borderline personality disorder: clinical and economic consequences |
| Q33462011 | Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24 months--European mania in bipolar longitudinal evaluation of medication |
| Q47878901 | Modifiable and non-modifiable factors associated with functional impairment during the inter-episodic periods of bipolar disorder |
| Q36630380 | Mood and anxiety spectrum as a means to identify clinically relevant subtypes of bipolar I disorder |
| Q41000171 | Mood self-assessment in bipolar disorder: a comparison between patients in mania, depression, and euthymia. |
| Q46732593 | More inclusive bipolar mixed depression definitions by requiring fewer non-overlapping mood elevation symptoms |
| Q36723359 | Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report. |
| Q44014376 | N-acetylcysteine for major depressive episodes in bipolar disorder |
| Q37376989 | Neural activity to intense positive versus negative stimuli can help differentiate bipolar disorder from unipolar major depressive disorder in depressed adolescents: a pilot fMRI study |
| Q36918687 | Neural correlates of treatment in adolescents with bipolar depression during response inhibition |
| Q43697094 | Neural correlates of treatment response in depressed bipolar adolescents during emotion processing |
| Q39002116 | Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume |
| Q47276081 | Non-Suicidal Self-Injury in Pediatric Bipolar Disorder: Clinical Correlates and Impact on Psychosocial Treatment Outcomes. |
| Q47588911 | Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder |
| Q35854309 | Number of prior episodes and the presence of depressive symptoms are associated with longer length of stay for patients with acute manic episodes |
| Q37653622 | Nutrition, Exercise, and Wellness Treatment in bipolar disorder: proof of concept for a consolidated intervention |
| Q36834290 | Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder |
| Q30559418 | Occupational disability in bipolar disorder: analysis of predictors of being on severe disablement benefit (PREBIS study data). |
| Q44266760 | Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling |
| Q42678439 | Olanzapine in treatment-resistant bipolar disorder |
| Q34432134 | Olanzapine: a review of its use in the treatment of bipolar I disorder |
| Q45664480 | One-year rehospitalization rates of patients with first-episode bipolar mania receiving lithium or valproate and adjunctive atypical antipsychotics |
| Q34509360 | Open-label adjunctive topiramate in the treatment of bipolar disorders. |
| Q46639807 | Open-label adjunctive topiramate in the treatment of unstable bipolar disorder |
| Q37124973 | Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. |
| Q38378462 | Organizational Learning Strategies and Verbal Memory Deficits in Bipolar Disorder. |
| Q24234152 | Oxcarbazepine for acute affective episodes in bipolar disorder |
| Q48336807 | Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study |
| Q34712339 | Paliperidone extended-release: does it have a place in antipsychotic therapy? |
| Q45771100 | Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). |
| Q48059809 | Performance of Bipolar Disorder Patients in Attention Testing: Comparison with Normal Controls and Among Manic, Depressive, and Euthymic Phases. |
| Q34052819 | Pharmacologic agents for the treatment of acute bipolar mania. |
| Q36909255 | Pharmacotherapeutic strategies for pediatric bipolar disorder |
| Q35641684 | Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder |
| Q50102258 | Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency |
| Q58803511 | Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight |
| Q64971674 | Predicting lithium treatment response in bipolar patients using gender-specific gene expression biomarkers and machine learning. |
| Q36538409 | Predictive factors for time to remission and recurrence in patients treated for acute mania: health outcomes of manic episodes (HOME) study |
| Q50596557 | Predictors and Moderators of Clinical Outcomes in Adolescents with Severe Mental Disorders After an Assertive Community Treatment. |
| Q38944918 | Predictors of functional status at service entry and discharge among young people with first episode psychosis. |
| Q45912951 | Predictors of substance use reduction in an epidemiological first-episode psychosis cohort. |
| Q57612656 | Preliminary results of a fine-grain analysis of mood swings and treatment modalities of bipolar I and II patients using the daily prospective life-chart-methodology |
| Q37098549 | Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder |
| Q38239296 | Prevalence and risk factors for suicidal behavior in young people presenting with first-episode psychosis in Hong Kong: a 3-year follow-up study |
| Q94544871 | Prevalence of Prediabetes and Diabetes Mellitus Type II in Bipolar Disorder |
| Q47739325 | Promoting medication adherence among patients with bipolar disorder: a multicenter randomized controlled trial of a multifaceted intervention. |
| Q41649722 | Prophylactic lithium treatment and cognitive performance in patients with a long history of bipolar illness: no simple answers in complex disease-treatment interplay |
| Q41964109 | Psychological functioning 1 year after a brief intervention using micronutrients to treat stress and anxiety related to the 2011 Christchurch earthquakes: a naturalistic follow-up |
| Q38374033 | Psychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression: A Randomized Controlled Trial |
| Q36088982 | Psychotherapy as monotherapy for the treatment of bipolar II depression: a proof of concept study |
| Q41438553 | Psychotherapy use in bipolar disorder: Association with functioning and illness severity |
| Q36145582 | Quetiapine as add-on treatment for bipolar I disorder: efficacy in preventing relapse of depressive episodes |
| Q33829611 | Quetiapine for acute bipolar depression: a systematic review and meta-analysis |
| Q44247110 | Quetiapine in the treatment of rapid cycling bipolar disorder. |
| Q44874572 | Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study |
| Q33411020 | Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation |
| Q34505551 | Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder |
| Q43931805 | Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers |
| Q47731026 | Rates and predictors of 18-months remission in an epidemiological cohort of 661 patients with first-episode psychosis |
| Q44375850 | Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania |
| Q94379686 | Rating Scales and Safety Measurements in Bipolar Disorder and Schizophrenia - A Reference Guide |
| Q42645283 | Recovery and functional outcomes following olanzapine treatment for bipolar I mania |
| Q24594534 | Regulation of glycogen synthase kinase‐3 during bipolar mania treatment |
| Q35736374 | Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study |
| Q33181790 | Response to placebo among bipolar I disorder patients experiencing their first manic episode |
| Q33650769 | Risk factors for an anxiety disorder comorbidity among Thai patients with bipolar disorder: results from the Thai Bipolar Disorder Registry |
| Q37803220 | Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder |
| Q42631462 | Risperidone monotherapy in manic inpatients: an open label, multicentre trial |
| Q50779681 | Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study. |
| Q37202889 | Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder. |
| Q37187450 | Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study |
| Q33650472 | Saving time and money: a validation of the self ratings on the prospective NIMH Life-Chart Method (NIMH-LCM) |
| Q48144134 | Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium |
| Q41974833 | Shaken but unstirred? Effects of micronutrients on stress and trauma after an earthquake: RCT evidence comparing formulas and doses |
| Q45754008 | Short TE (7) Li-MRS confirms Bi-exponential lithium T2 relaxation in humans and clearly delineates two patient subtypes |
| Q35930169 | Six-month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder |
| Q92064052 | Smartphone Monitoring of Mood Instability in Young Depressed Patients: A Latent-class Analyses |
| Q40860046 | Statistical approaches to trial durations in episodic affective illness. |
| Q55435322 | Study Protocol for a Randomized Double Blind, Placebo Controlled Trial Exploring the Effectiveness of a Micronutrient Formula in Improving Symptoms of Anxiety and Depression. |
| Q47607868 | Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design |
| Q43568188 | Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders |
| Q51054683 | Successful treatment of bipolar disorder II and ADHD with a micronutrient formula: a case study. |
| Q51425973 | Suicidal attempts in bipolar disorder: results from an observational study (EMBLEM). |
| Q45277258 | Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression |
| Q37613752 | Switching bipolar disorder patients treated with clozapine to another antipsychotic medication: a mirror image study |
| Q64938356 | Symptom Dimensions and Trajectories of Functioning Among Bipolar Youth: A Cluster Analysis. |
| Q50782060 | Targeted scoring criteria reduce variance in global impressions. |
| Q57709578 | The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia |
| Q63353169 | The Cost of Relapse for Patients with a Manic/Mixed Episode of Bipolar Disorder in the EMBLEM Study |
| Q44311423 | The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment |
| Q51020789 | The InterSePT scale for suicidal thinking reliability and validity. |
| Q45935875 | The Life Functioning Questionnaire (LFQ): a brief, gender-neutral scale assessing functional outcome. |
| Q37305801 | The Mood Disorder Burden Index: a scale for assessing the burden of caregivers to adults with unipolar or bipolar disorder |
| Q36010076 | The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample |
| Q40656925 | The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. |
| Q33894649 | The clinical global impressions scale: applying a research tool in clinical practice |
| Q33272500 | The improved Clinical Global Impression Scale (iCGI): development and validation in depression |
| Q47873483 | The influence of current mood state, number of previous affective episodes and predominant polarity on insight in bipolar disorder. |
| Q31119259 | The management of bipolar mania: a national survey of baseline data from the EMBLEM study in Italy |
| Q38246661 | The potential role of atypical antipsychotics in the treatment of panic disorder |
| Q51005927 | The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. |
| Q44207549 | The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype |
| Q38025454 | The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence |
| Q57612764 | The social, psychopathological and consumer context of rate of symptom improvement in acute mania |
| Q30493934 | The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder |
| Q37468555 | The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder |
| Q24202532 | Tiagabine for acute affective episodes in bipolar disorder |
| Q24234313 | Tiagabine in the maintenance treatment of bipolar disorder |
| Q24245366 | Tiagabine in the maintenance treatment of bipolar disorders |
| Q24244993 | Tiagabine in the treatment of acute affective episodes in bipolar disorder |
| Q42690598 | Tiagabine in treatment refractory bipolar disorder: a clinical case series. |
| Q37128097 | Time to relapse and remission of bipolar disorder: findings from a 1-year prospective study in Thailand |
| Q59329610 | Topical Analgesia with Lidocaine Plus Diclofenac Decreases Pain in Benign Anorectal Surgery: Randomized, Double-blind, and Controlled Clinical Trial |
| Q73634791 | Topiramate as add-on treatment for patients with bipolar mania |
| Q38807333 | Trait-related alterations of N-acetylaspartate in euthymic bipolar patients: A longitudinal proton magnetic resonance spectroscopy study |
| Q41663038 | Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings |
| Q46015639 | Trauma exposure and post-traumatic stress disorder in bipolar disorder. |
| Q36604329 | Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice |
| Q35203680 | Treatment implications of predominant polarity and the polarity index: a comprehensive review |
| Q36188647 | Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study |
| Q30361078 | Treatment moderators of child- and family-focused cognitive-behavioral therapy for pediatric bipolar disorder. |
| Q35103972 | Treatment of bipolar disorder in the Netherlands and concordance with treatment guidelines: study protocol of an observational, longitudinal study on naturalistic treatment of bipolar disorder in everyday clinical practice |
| Q47560984 | Treatment outcomes of acute bipolar depressive episode with psychosis |
| Q43119910 | Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics. |
| Q87815172 | Two years' outcome of acute mania in bipolar disorder: different effects of age and age of onset |
| Q90231600 | Uncharted Waters: Treating Trauma Symptoms in the Context of Early Psychosis |
| Q35025965 | Unique design issues in clinical trials of patients with bipolar affective disorder |
| Q35575996 | Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorder. |
| Q38020283 | Use of adjunctive stimulants in adult bipolar depression |
| Q44500090 | Use of micronutrients attenuates cannabis and nicotine abuse as evidenced from a reversal design: a case study |
| Q43869831 | Utility of the daily prospective National Institute of Mental Health Life-Chart Method (NIMH-LCM-p) ratings in clinical trials of bipolar disorder |
| Q42614417 | Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: an open-label trial. |
| Q22252976 | Valproate for acute mood episodes in bipolar disorder |
| Q48281390 | Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression |
| Q36463481 | Verbal and Visual Memory Impairments in Bipolar I and II Disorder |
| Q37138425 | What goes up must come down: the burden of bipolar depression in youth |
| Q47435866 | White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder |
| Q58308202 | Work-Related Subjective Experiences, Work-Related Self-Efficacy, and Career Learning Among People with Psychiatric Disabilities |
| Q39711081 | Work-related subjective experiences among community residents with schizophrenia or schizoaffective disorder |
| Q86485574 | Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort |
| Q34637512 | Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. |
| Q28273414 | Zotepine loading in acute and severely manic patients: a pilot study |
| Q28281197 | The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Tria |
Search more.